Cargando…

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease

AIM: Treatment of frequently relapsing or steroid‐dependent minimal change disease (MCD) in children and adults remains challenging. Glucocorticoids and/or other immunosuppressive agents are the mainstay of treatment, but patients often experience toxicity from prolonged exposure and may either beco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papakrivopoulou, Eugenia, Shendi, Ali M., Salama, Alan D., Khosravi, Maryam, Connolly, John O., Trompeter, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026064/ https://www.ncbi.nlm.nih.gov/pubmed/26860320 http://dx.doi.org/10.1111/nep.12744

Ejemplares similares

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
por: Liu, Diankun, et al.
Publicado: (2021)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
por: Zhang, Jian, et al.
Publicado: (2023)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

DNA methylation changes between relapse and remission of minimal change nephrotic syndrome
por: Kobayashi, Yasuko, et al.
Publicado: (2012)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Xue, Cheng, et al.
Publicado: (2020)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
por: Webendörfer, Maximilian, et al.
Publicado: (2021)

Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome
por: Chen, Yewei, et al.
Publicado: (2021)

Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy
por: Janardan, Jyotsna, et al.
Publicado: (2014)

Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children
por: Gao, Xia, et al.
Publicado: (2021)

Minimal Change Nephrotic Syndrome Relapse after 52 Years of Remission: A Case Report
por: Yamabe, Hideaki, et al.
Publicado: (2018)

Rituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2022)

Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease
por: Tanabe, Kaori, et al.
Publicado: (2021)

Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series
por: Knight, A., et al.
Publicado: (2013)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Induction of Remission is Difficult due to Frequent Relapse during Tapering Steroids in Korean Patients with Polymyalgia Rheumatica
por: Kim, Hyoun-Ah, et al.
Publicado: (2012)

IgM deposition is a risk factor for delayed remission and early relapse of the pediatric minimal change disease
por: Ju, Tao, et al.
Publicado: (2023)

CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease
por: Teh, Yoong Mond, et al.
Publicado: (2021)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience
por: NASEHI, Mohammad Mahdi, et al.
Publicado: (2022)

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
por: Hogan, Julien, et al.
Publicado: (2020)

Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan
por: Takura, Tomoyuki, et al.
Publicado: (2017)

Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease
por: Guan, Nan, et al.
Publicado: (2023)

Remissions and Relapses in Insular Sclerosis
Publicado: (1904)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Tozinameran: Relapse of minimal change disease
Publicado: (2022)

How frequent is spontaneous remission of neuroblastomas? Implications for screening.
por: Carlsen, N. L.
Publicado: (1990)

Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
por: Kannan, Lakshmi
Publicado: (2022)

Wegener's Granulomatosis Presenting with Pachymeningitis: Clinical and Imaging Remission by Rituximab
por: Just, Søren Andreas, et al.
Publicado: (2011)

Remission Achieved in Refractory Advanced Takayasu Arteritis Using Rituximab
por: Ernst, D., et al.
Publicado: (2012)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020)

Acute Kidney Injury and Remission of Proteinuria in Minimal Change Disease
por: Yamamoto, Ryohei, et al.
Publicado: (2022)

Spontaneous remission of idiopathic minimal change disease in a cat
por: Broadbridge, Catherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2v22opaij3628uvbn6123cgqvj